The risk of flare was reduced in the intervention group compared to the control group (IRR: 0.7252; 95% CI: 0.4997–1.0578), but this did not reach statistical significance. 170 A similar, more recent, study, NOR-DRUM, evaluated the use of therapeutic drug monitoring of patients commencing infliximab in a mixed population of 411 patients with different autoimmune conditions in Norway.
1
—
—